Magnesium Glycinate vs Threonate in Perimenopause: Two Forms Hit Different Sleep Targets
Sleep falls apart in the perimenopausal transition. In women 35–55, sleep onset lengthens, awakenings cluster around 3–4 a.m., and deep sleep duration shrinks. The simultaneous effect of nighttime estrogen and progesterone fluctuations on GABA signaling and thermoregulation. Magnesium supplementation is the most-suggested non-hormonal option for this period, but data are accumulating that the form determines which circuit gets engaged.
The Schuster 2025 trial reported meaningful improvements in PSQI (Pittsburgh Sleep Quality Index), shortened sleep onset, and reduced nocturnal awakenings on bisglycinate 250mg daily. The Hausenblas 2024 trial reported increased deep-sleep duration plus simultaneous improvement in working memory and cognitive scores on L-threonate 1g (equivalent to 144mg elemental magnesium). NCT07235878, a 12-week perimenopause RCT, is currently running a head-to-head comparison.
The branching point between forms is blood-brain barrier crossing. Magnesium glycinate (bound to glycine) has high GI absorption with minimal side effects (diarrhea). Glycine itself is an inhibitory neurotransmitter — adding nervous system calming, muscle relaxation, and indirect GABA potentiation. Sleep onset shortening and reduced awakenings are its standout clinical effects.
Magnesium threonate is a specialized form bound to L-threonate, designed by MIT’s Liu Hao team to cross the blood-brain barrier. While other magnesium forms barely raise brain concentrations, threonate produces measurable increases in brain magnesium. Animal studies show synaptic density increase; human trials show working memory and cognitive speed gains. The clearest sleep effect is extended slow-wave (deep) sleep.
The clinical patterns observed in perimenopausal women:
- Sleep onset difficulty + nocturnal awakenings: glycinate 250–400mg in the evening with food → onset shortening within 1–2 weeks
- Deep sleep deficit + morning fatigue + cognitive fog: threonate 1g (elemental 144mg) → cumulative effect at 3–4 weeks
- Both patterns: glycinate + threonate matrix (evening glycinate + lunch or afternoon threonate)
Other forms in context:
- Citrate: useful for constipation; weaker sleep effect than glycinate. GI irritation possible
- Oxide: ~4% absorption. Effectively a laxative, not for sleep
- Chloride: suited for topical use (Epsom salt baths). Oral absorption is average
- Taurate: cardiovascular benefits in some trials; sleep data limited
Daily elemental magnesium ceiling is 200–400mg as a standard. Glycinate 250mg ≈ 50mg elemental; threonate 1g ≈ 144mg elemental. Take both with food. Patients with reduced kidney function (eGFR < 30) need physician oversight, as do those on diuretics or heart failure medications.
Magnesium-rich foods: pumpkin seeds (156mg per 28g), spinach (78mg per half cup), black beans (120mg per cup), almonds (80mg per 28g), dark chocolate (64mg per 28g). An estimated 70–80% of Korean women fail to reach the 320mg daily recommendation. Diet plus supplementation makes sense as a combined approach.
Perimenopausal sleep collapse needs matrix thinking, not single-supplement promises. Magnesium (glycinate or threonate), vitamin D, omega-3, caffeine moderation after 2 p.m., consistent bedtimes and wake times, bedroom temperature 18–20°C — these create meaning when working in parallel. The promise that one form of magnesium solves all sleep problems does not survive contact with the neuroendocrine reality of perimenopause.